Polo-like kinase 1 contributes to the tumorigenicity of BEL-7402 hepatoma cells via regulation of Survivin expression

Cancer Letters

Volumn 303, Issue 2, 2011, Pages 92-98

  He, Zili ^a,c   Wu, Jinshu ^a   Dang, Hongsheng ^b   Lin, Hui ^c   Zheng, He ^c   Zhong, Dewu ^c  

^a HUNAN PROVINCIAL PEOPLE S HOSPITAL   (China)

^b HUBEI UNIVERSITY OF MEDICINE   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

BEL 7402 cells; Caspase 3; Polo like kinase 1; Survivin; Xenograft model

Indexed keywords

CASPASE 3; POLO LIKE KINASE 1; SMALL INTERFERING RNA; SURVIVIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER TISSUE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVITY; FLOW CYTOMETRY; HEPATOMA CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MITOSIS INHIBITION; MOUSE; NICK END LABELING; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; RNA INTERFERENCE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RNA, SMALL INTERFERING;

MUS MUSCULUS;

EID: 79952043881     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.01.007     Document Type: Article

References (40)

1. Jelic S. Hepatocellular carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 2009, 20(Suppl. 4):41-45.
2. Aravalli R.N., Steer C.J., Cressman E.N. Molecular mechanisms of hepatocellular carcinoma. Hepatology 2008, 48:2047-2063.
3. Zhu A.X., Clark J.W. Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy. Oncologist 2009, 14:67-69.
4. Zhang X.F., Meng B., Qi X., Yu L., Liu C., Liu X.M., Wang B., Pan C.E., Lv Y. Prognostic factors after liver resection for hepatocellular carcinoma with hepatitis B virus-related cirrhosis: surgeon's role in survival. Eur. J. Surg. Oncol. 2009, 35:622-628.
5. Li N., Lai E.C., Shi J., Guo W.X., Xue J., Huang B., Lau W.Y., Wu M.C., Cheng S.Q. A comparative study of antiviral therapy after resection of hepatocellular carcinoma in the immune-active phase of hepatitis B virus infection. Ann. Surg. Oncol. 2009.
6. Nathan H., Schulick R.D., Choti M.A., Pawlik T.M. Predictors of survival after resection of early hepatocellular carcinoma. Ann. Surg. 2009, 249:799-805.
7. Jan Y.J., Ko B.S., Hsu C., Chang T.C., Chen S.C., Wang J., Liou J.Y. Overexpressed focal adhesion kinase predicts a higher incidence of extrahepatic metastasis and worse survival in hepatocellular carcinoma. Hum. Pathol. 2009, 40:1384-1390.
8. Forner A., Ayuso C., Varela M., Rimola J., Hessheimer A.J., de Lope C.R., Reig M., Bianchi L., Llovet J.M., Bruix J. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?. Cancer 2009, 115:616-623.
9. Fabregat I., Roncero C., Fernandez M. Survival and apoptosis: a dysregulated balance in liver cancer. Liver Int. 2007, 27:155-162.
10. Hamanaka R., Smith M.R., O'Connor P.M., Maloid S., Mihalic K., Spivak J.L., Longo D.L., Ferris D.K. Polo-like kinase is a cell cycle-regulated kinase activated during mitosis. J. Biol. Chem. 1995, 270:21086-21091.
11. Golsteyn R.M., Lane H.A., Mundt K.E., Arnaud L., Nigg E.A. The family of polo-like kinases. Prog. Cell Cycle Res. 1996, 2:107-114.
12. Lane H.A., Nigg E.A. Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J. Cell Biol. 1996, 135:1701-1713.
13. Arnaud L., Pines J., Nigg E.A. GFP tagging reveals human polo-like kinase 1 at the kinetochore/centromere region of mitotic chromosomes. Chromosoma 1998, 107:424-429.
14. Arai T., Haze K., Iimura-Morita Y., Machida T., Iida M., Tanaka K., Komatani H. Identification of beta-catenin as a novel substrate of polo-like kinase 1. Cell Cycle 2008, 7:3556-3563.
15. Liu X., Lei M., Erikson R.L. Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol. Cell. Biol. 2006, 26:2093-2108.
16. Lei M., Erikson R.L. Plk1 depletion in nontransformed diploid cells activates the DNA-damage checkpoint. Oncogene 2008, 27:3935-3943.
17. He Z.L., Zheng H., Lin H., Miao X.Y., Zhong D.W. Overexpression of polo-like kinase1 predicts a poor prognosis in hepatocellular carcinoma patients. World J. Gastroenterol. 2009, 15:4177-4182.
18. Holtrich U., Wolf G., Brauninger A., Karn T., Bohme B., Rubsamen-Waigmann H., Strebhardt K. Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors. Proc. Natl Acad. Sci. USA 1994, 91:1736-1740.
19. Petronczki M., Lenart P., Peters J.M. Polo on the rise-from Mitotic entry to cytokinesis with Plk1. Dev. Cell 2008, 14:646-659.
20. Kishi K., van Vugt M.A., Okamoto K., Hayashi Y., Yaffe M.B. Functional dynamics of polo-like kinase 1 at the centrosome. Mol. Cell. Biol. 2009, 29:3134-3150.
21. Yamamoto Y., Matsuyama H., Kawauchi S., Matsumoto H., Nagao K., Ohmi C., Sakano S., Furuya T., Oga A., Naito K., Sasaki K. Overexpression of polo-like kinase 1 (PLK1) and chromosomal instability in bladder cancer. Oncology 2006, 70:231-237.
22. Smith M.R., Wilson M.L., Hamanaka R., Chase D., Kung H., Longo D.L., Ferris D.K. Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem. Biophys. Res. Commun. 1997, 234:397-405.
23. Gunawardena R.W., Siddiqui H., Solomon D.A., Mayhew C.N., Held J., Angus S.P., Knudsen E.S. Hierarchical requirement of SWI/SNF in retinoblastoma tumor suppressor-mediated repression of Plk1. J. Biol. Chem. 2004, 279:29278-29285.
24. Liu X., Erikson R.L. Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc. Natl Acad. Sci. USA 2003, 100:5789-5794.
25. Hayashi P.H., Di Bisceglie A.M. The progression of hepatitis B- and C-infections to chronic liver disease and hepatocellular carcinoma: presentation, diagnosis, screening, prevention, and treatment of hepatocellular carcinoma. Infect. Dis. Clin. North Am. 2006, 20:1-25.
26. Studach L.L., Rakotomalala L., Wang W.H., Hullinger R.L., Cairo S., Buendia M.A., Andrisani O.M. Polo-like kinase 1 inhibition suppresses hepatitis B virus X protein-induced transformation in an in vitro model of liver cancer progression. Hepatology 2009, 50:414-423.
27. Pellegrino R., Calvisi D.F., Ladu S., Ehemann V., Staniscia T., Evert M., Dombrowski F., Schirmacher P., Longerich T. Oncogenic and tumor suppressive roles of polo-like kinases in human hepatocellular carcinoma. Hepatology 2010, 51:857-868.
28. Schoffski P., Blay J.Y., De Greve J., Brain E., Machiels J.P., Soria J.C., Sleijfer S., Wolter P., Ray-Coquard I., Fontaine C., Munzert G., Fritsch H., Hanft G., Aerts C., Rapion J., Allgeier A., Bogaerts J., Lacombe D. Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network of Core Institutes (NOCI). Eur. J. Cancer 2010, 46:2206-2215.
29. Gerster K., Shi W., Ng B., Yue S., Ito E., Waldron J., Gilbert R., Liu F.F. Targeting polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2010, 77:253-260.
30. Yim E.K., Tong S.Y., Ho E.M., Bae J.H., Um S.J., Park J.S. Anticancer effects on TACC3 by treatment of paclitaxel in HPV-18 positive cervical carcinoma cells. Oncol. Rep. 2009, 21:549-557.
31. Sah N.K., Khan Z., Khan G.J., Bisen P.S. Structural, functional and therapeutic biology of survivin. Cancer Lett. 2006, 244:164-171.
32. Tamm I., Wang Y., Sausville E., Scudiero D.A., Vigna N., Oltersdorf T., Reed J.C. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 1998, 58:5315-5320.
33. Perry D.K., Smyth M.J., Stennicke H.R., Salvesen G.S., Duriez P., Poirier G.G., Hannun Y.A. Zinc is a potent inhibitor of the apoptotic protease, caspase-3. A novel target for zinc in the inhibition of apoptosis. J. Biol. Chem. 1997, 272:18530-18533.
34. Li P., Nijhawan D., Wang X. Mitochondrial activation of apoptosis. Cell 2004, 116. S57-59, 52p following S59.
35. Colnaghi R., Wheatley S.P. Liaisons between Survivin and PLK1 during cell division and cell death. J. Biol. Chem. 2010.
36. Altieri D.C. Validating Survivin as a cancer therapeutic target. Nat. Rev. Cancer 2003, 3:46-54.
37. Feng Y.B., Lin D.C., Shi Z.Z., Wang X.C., Shen X.M., Zhang Y., Du X.L., Luo M.L., Xu X., Han Y.L., Cai Y., Zhang Z.Q., Zhan Q.M., Wang M.R. Overexpression of PLK1 is associated with poor survival by inhibiting apoptosis via enhancement of Survivin level in esophageal squamous cell carcinoma. Int. J. Cancer 2009, 124:578-588.
38. Fortugno P., Wall N.R., Giodini A., O'Connor D.S., Plescia J., Padgett K.M., Tognin S., Marchisio P.C., Altieri D.C. Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J. Cell Sci. 2002, 115:575-585.
39. Connell C.M., Wheatley S.P., McNeish I.A. Nuclear Survivin abrogates multiple cell cycle checkpoints and enhances viral oncolysis. Cancer Res. 2008, 68:7923-7931.
40. Song Z., Wu M. Identification of a novel nucleolar localization signal and a degradation signal in Survivin-deltaEx3: a potential link between nucleolus and protein degradation. Oncogene 2005, 24:2723-2734.